New Investor Q&A The following is lengthy mock Q
Post# of 29
Posted On: 10/19/2014 5:46:12 PM
New Investor Q&A
The following is lengthy mock Q&A for a new investor that wants to learn more. It is a very long post, but explains a ton. At the end is the timeline for EPGL since it's inception back in the summer of 2012.
EPGL Medical Sciences.
www.epglmed.com
1. What is EPGL???
Epgl Global Communications, aka EPGL Medical Sciences, is a new biomedical device marketing company. The Company is currently working to invent and develop cutting edge medical device technology products including biomedical devices which utilize Bio-Micro-Electro Mechanical Systems technology (Bio-MEMS).
2. Bio-MEMS????
Yes, EPGL is currently focused and centered around the BioMEM field. BioMEMS are micro-electro-mechanical systems. Mechanical parts and microfabrication technologies made suitable for biological applications. A broad definition for bio-MEMS can be used to refer to the science and technology of operating at the microscale for biological and biomedical applications, which may or may not include any electronic or mechanical functions.
Bio-MEMS is one of the fastest growing and promising new frontiers in medical technology today with possibilities in both medical diagnostic and treatment applications.
http://en.wikipedia.org/wiki/Bio-MEMS
Currently EPGL has as it's chief scientist, former DARPA and Raytheon Engineer/Inventor and expert BioMEM scientist, Dr. David Markus, in which he and EPGL laid plans to develop some of the smartest and tech saavy products ever seen.
September 24th, 2012
EP Global Communications, Inc. Lands One of the World's Leading Biomedical Engineers.
David T. Markus holds a Ph.D. in Biomedical Engineering and a MS in Electrical Engineering with an emphasis in MEMS Microelectronics and Biomedical. The worldwide market for Bio-MEMS medical technology is estimated to grow into hundreds of billions of dollars over the next several years in healthcare as well as other technological markets. The Company plans to aggressively pursue new technology opportunities in this field of medical technology.
EPGL hires David T. Markus Ph.D
With the hiring of Dr. David Markus, EPGL exposed itself to the amazing world of BioMem technology. With the worlds leading scientist and patent holder of such technology, EPGL explored the idea of branching into that field. They came up with platform based technology coded 'Top Spin' that could put EPGL at the top of the food chain.
June 18th, 2013
EPGL Medical Unveils New Devices and Intellectual Property Under EP Global Communications, Inc. Ownership
Advanced Device Prototypes on the Way Along with FDA 510k and PMA Applications.
New Devices and Intellectual Property
1. A new advanced ablation device for nerve pain treatment in the back.
2. A new advanced ablation device for nerve treatment of Facial Glabballar Frowning.
3. A new advanced device for elimination of facial wrinkles.
4. A new advanced Epidural device.
5. A new advanced power source for TopSpin medical devices.
6. A new and promising device for treatment of Retinitis Pigmentosa
7. A new and promising device for treatment of Macular Degeneration
8. A new and promising treatment for Hearing Loss
9. A new more accurate treatment for trigger points in the muscles (MPTT)
10. A new advanced device for treatment of prostate tumors.
11. A new advanced endoscopic device.
12. A new advanced device for delivery of micron sized drug payloads.
13. A new advanced device for delivery of micro mechanical devices into the body.
14. A new advanced device for biopsy.
15. A new advanced device for stem cell treatment delivery.
16. A new advanced contact lens device.
Feel free to check out these articles based upon Dr. Markus and EPGL's technology.
Will EPGL's TopSpin Serve Up the Next Generation of Medical Devices?
Company Designs MEMS-Based Energy Harvester for Contact Lenses
3. A smart contact lens? Sounds f'n cool as hell!
It sure is! Checkout these two PR's regarding such work, as well as other actions.
EPGL Medical Invents Self Powered Contact Lenses for Medical and Consumer Applications
EPGL Medical Invents New Cell Regeneration Technology For Eye Disease
Then in December of 2013, they were selected by a multi-billion dollar NYSE company to integrate EPGL's tech into theirs.
December 16th, 2013
EPGL Technology Selected by Major Corporation for Development
In a first for the company, one of EPGL's advanced technologies has been selected by a multi-billion dollar, NYSE publicly traded industry leader for development and integration into new products. "This is the biggest development for our company in its history," said David T. Markus PhD.”
EPGL Technology Selected by Major Corporation for Development
4. Wow! Who's the company?
Due to a non-disclosure agreement (NDA) between the company and EPGL, which is a common business practice with these types of deals, EPGL is currently unable to divulge who the company is or the terms of the deal. But the information is going to be released soon.
Since then investors have been speculating on who the company is and what impact it will have on EPGL.
Then EPGL announced the following"
Quote:
EPGL Announced Advanced Contact Lens Technology in August of 2013. Since then our technology and know how has caught the eyes of the world's leading companies in the field. Now, EPGL is on the forefront of innovating the technology and EPGL MEMS will be inside the world's most advanced contact lenses as we move into this new revolution of smart, wearable technology.
EPGL technologies are on the cutting edge and in demand. We believe current dedicated shareholders will be proven to be "visionary".
That pretty much summed up that they are working on a smart contact lens. Then they soon followed up that announcement with:
Quote:
EPGL is leading the advance MEMS technology design and product development for one of the largest companies in its field. The relationship has expanded under phase two and involves co -ownership of product technologies under development. All EPGL technologies are involved. The technology and products will be manufactured by the NYSE company branded under its name and distributed worldwide, by that Company and others affiliated. EPGL's role is that of research, design, development and ownership of the various technology applications. We are developing an "open source" platform with this company to enable many other organizations and entities to create new products with a new platform. EPGL shareholders should realize that this situation is very real and developing. We are getting very much closer to the time we can reveal all. This will happen no later than August 29, 2014.
EPGL is unlike any other OTC Pink Sheet company at this time. Shareholders are right to be excited about our future. By the way,EPGL and our partners could make an announcement sooner that August 29, 2014.
5. Doesn't Google want to do this???!!! Or some other behemoth? I read somewhere that Google was trying to make a smart contact lens.
They all want to, but none of them, other than EPGL, has the technology to make it all work. It's still very 'new'. But Dr. Markus has been working on it for the past 2+ decades. Google made a big deal a few months ago about how they were developing a smart contact lens. However, to their dismay, they failed at being able to make it work and have reached out to EPGL for help, as well as contact lens giant, Novartis.
6. Hot damn! So, is it possible that the mystery company could be Google?
EPGL summed that up best on July 18th, 2014 when they updated shareholders.
Quote:
It can now be revealed that both Novartis and Google reached out to our development team members in recent weeks and months. This fact should be a clue to the gravity and know-how of our team in both BioMEMS and manufacturing of smart contact lenses. We intend to set the industry's standard with our enabling technology. Who are we teamed up with? Who will ultimately include EPGL originated technology.
7. Holy cow! Well that explains why the stock has been hot as of late. I really want to invest in this. But at the end of the day, this is still a Pink Sheet Company. How am I to believe what I am seeing unfold? Aren't all pink sheet companies bogus in one way or another. I've been fooled many time over in this arena and have lost thousands of dollars trusting Pink Sheet Companies.
Good question. I too, have lost thousands in this arena. The one thing that those company's don't have, and what EPGL has....is ACCOUNTABILITY. Comes down to logical thinking. This will be a bit lengthy, but its a good deduction of why you should separate EPGL when thinking of your typical Pink Sheet Company.
Typical pinksheet stories have companies formed from shells after massive R/S's take out all previous existing shareholders. 1/1000 and up. EPGL executed a 1/10, during it's positive restructuring, 2 years ago which kept all existing shareholders in. The majority of those investors have stayed and added more shares from .001 to where we are now. Despite fear mongering by a few, those investors, including myself, have increased our portfolio value by 5-6 figures by owning EPGL over the past 2 years. No other stock has ever given me a 3600% increase in 2 years. Why did I stay in? I applied simple logic.
Typical Pinksheet stories have companies that are created by a shady financier and their seed shareholders, sponsored by corrupt individual lawyers and corrupt accountants whom the majority of which are listed on the OTC's main page. EPGL was created by PwC, one of the most prestigious and reputable accounting firms on the planet, trusted by and given the opportunity by the federal courts, and monitored by the SEC, as part of a liquidation process whereas, EPGL was to be restructured and become a medical device company, with the capabilities of being a profitable company, wherein, the value of such a company will eventually lead to PwC recouping lost capital for defrauded investors from a corrupt hedge fund.
Typical pinksheet stories have companies that have no accountability. EPGL and PwC are accountable to the investors PwC needs to assist and retrieve funds for as well as the Federal Courts that put PwC in charge. Basically, put, if EPGL is lying, then that means PWC is in cahoots with it. You think that's a possibility? Go to this site and see if you think PwC is scamming the investors it's helping.
September 15th, 2013
AJW Investor Update
AJW Investor Update
Typical pinksheet companies have promoters that pump the stock. The promoters, and or the agencies that actually retain them, are often paid in stock for their services, or will front load, i.e. buy stock out of the market in advance of a coming 'Pump & Dump' campaign. And of course, they definitely know when a Pump & Dump campaign will launch and may be intimately involved in the timing and content of press releases. EPGL does not have any such promoters, nor has there been a P&D after nearly 2 years of being in business.
Typical Pinksheet stories are loaded with toxic debt. This is simple. EPGL has $0.00 toxic debt.
Typical Pinksheet stories dilute shares immediately and often as possible. EPGL has not diluted one single share in nearly 2 years of operations. nor have they diluted since their shares have become unrestricted.
Typical Pinksheet stories don't have a product. EPGL, although the MPDD/MPTT has been given to their partners to market and produce, they own the patent rights and will make royalties off of the sales. The devices are proven to be real as they have been demonstrated on national news shows, etc, etc.
Typical Pinksheet stories don't have world renowned scientists working for them. Dr. David Markus is well known throughout his field of expertise. Having worked with DARPA, Raytheon, etc, etc, his reputation speaks for itself. Simple, elementary logic states that he will not damage it by belonging to a corrupt company or a company that can't see things though. Given the well documented work that Dr. David Markus has been a part of over the past decades, what he is producing as the lead scientist for EPGL, it is proof enough that their tech is more than believable and well worth the risk of investing in the company.
Typical Pinksheet stories don't have billion dollar NYSE companies partnering up with them. Granted we have no proof that a company did with EPGL because they had to sign an NDA agreement, but it would be completely illogical for both PwC and EPGL to lie about it given whats at stake. There is just no proof or logic to support any claim that such a deal does not exist. It would be foolish for any investor to think so.
I could go on and on and on and on and on. You get it.
8. Wow. I never looked at it like that before. But if I may, I've noticed thru my initial DD, that EPGL is not registered with the SEC. I've heard that companyies that de-registered never re-register. Does that mean that EPGL will never re-register? And what about the name change I've heard about?
It does not mean that at all. This can be confusing. It's important you focus when reading this. And use logic when thinking about that your question.
Very rarely, if ever, does a company that de-registers with the SEC, re-register. That's because after that company de-registers, it goes BK and disappears. If it doesn't go BK, it remains the same company, with the same product and the same problems that caused it to de-register in the first place. No product, tons of toxic debt, bad management, etc, etc. With no chance to realistically create revenue. It then becomes a shell.
EPGL, on the other hand, is an entirely new company! It is not the same company that had the name and ticker that de-registered! The only similarity it has with the former company is the name and the ticker. EPGL has new management, zero debt, a pipeline that is going to take the lead in a brand new market place, a billion dollar NYSE company funding EPGL's R&D, etc, etc. It's a new company that inherited only the name and the ticker. That's all. You understand? Going by the logic, "EPGL de-registered with the SEC. No company has ever re-registered with the SEC after it de-registered. Therefore, EPGL will not re-register" is an extremely illogical and reckless way to deduce things. EPGL Medical Sciences...the company you see before you, never de-registered because it was never registered in the first place. Once you read between the lines, everything becomes clear and obvious.
It is EPGL's plan to officially change their name when they re-register with the SEC. Which they had planned to do when they finished up the house keeping from the liquidation process. The former company made quite a mess of the ticker. Then things began to shift towards BioMEMs and the possibility of being bought out dramatically increased. EPGL put off re-registering simply put because they may never have to. Why go through all of that if you get bought out? Right now, EPGL is waiting to see what happens. Once the dust settles they will re-register and be formerly recognized as 'EPGL Medical Sciences' by the powers that be.
9. Yeah, I get it. Seems logical!! Thanks!!! So, Back to the NYSE company partnering up with EPGL. How do you think it will go down? I know you can only speculate, but I know nothing of these types of deals. Can you speculate for me? Give me an idea of what is possible???
Sure, I'll try and explain it way I personally feel the deal will go down. The deal in my eyes, will most likely work like this.....
The way it is most likely going to work is that the NYSE partner is going to be handling all of EPGL's operating costs. R&D, manufacturing, etc, etc. In simple terms, EPGL will work as the NYSE Company's R&D Department. All expenses paid and 50% of all revenues generated.
The NYSE Company will most likely be handling of all of the R&D costs associated with making the technologies/products a reality. from the FDA 501k's, Patent processing, the NYSE Company's distribution channels, Legal Issues, etc, etc. The NYSE company will be absorbing the majority of risk and will be giving EPGL a good cut.
Also remember, EPGL's tech is not the product. EPGL's specific tech makes the product work. This company wants to integrate all of EPGL's tech into their products. Then, if another company comes along and wants EPGL's tech integrated into their product, the NYSE Company gets a 50% piece of that. It's all a win-win situation. Additionally, having everything under the NYSE Company's name, a 7 billion dollar proven industry giant, gives the tech added legitemacy and helps speed things along and create other opportunities.
Again, EPGL will be spending next to nothing, while it works to integrate it's tech into the NYSE's Company's products. Then, EPGL gets co-ownership of the specific product and half the revenues that will be generated.
It would appear that there won't be a buyout simply because the NYSE Company, at this current time, can't afford the number EPGL/PwC was likely asking. Doesn't rule it out in the future, once the revenues start pouring in. You can bet that the NYSE Company will have 1st right of refusal when it does come to EPGL being bought out.
All and all, this is all just my theory. Won't know for sure until the full details are actually released. But in reality, it is the most likely way things are to be done.
10. Awesome! Thanks. So as you mentioned above, regarding EPGL's product, its not so much that EPGL's tech is the product, but more so that EPGL's tech is what gives the product life? Makes the product function?
Yes. In layman's terms. And it opens up EPGL to other company's to partner up with as well that have a product in BioMEM's they want to have produced.
11. All of this is very interesting. One more thing, if I may. I read that EPGL had a device called the MPDD and were close to finishing up development on the MPTT. What ever became of those devices?
Good question. When EPGL first started out 2 years ago, the MPDD was their initial product. A device that detected the true source of back pain. The MPTT was a dveice being developed that could then treat that pain. Of course, like all start up bio techs, there is an evolution that occurs. As Dr. Markus' BioMEM platform started to advance, it became clear to EPGL that the road they should take should center more on BioMEMS and that they should work to strengthen their position in that market, as they are frontrunners. So, EPGL reconfigured their business plan to better suit a more profitable and more esteemed plan of action in that field. EPGL's distributor took over all aspects of the MPDD and will take the lead in marketing it and selling it, etc. It will also take the lead in dealing with the MPTT. EPGL will sit back and collect royalties, increasing it's revenue in addition to the potential revenue it will incur from it's bioMEM tech.
From EPGL's CEO Michael Hayes regarding this process:
Quote:
As EPGL has now transitioned to focus on a major MEMS technology development, the Company is transferring all MPD1 and MPTT future development and marketing to our distribution partners in Asia and the United States. As such, the MPD1 activity which has been stalled since 4th Quarter 2013, will begin to have new life in 2014 and our partners will pick up the ball and aggressively pursue sales of MPD1 starting 3rd Quarter 2014. As a result of this, EPGL will be enabled to focus 100% on major development projects which are important to the Company while reinvigorating the MPD1 and MPTT projects under our partners efforts. Q1 2014 financials, to be released within 72 hours, will reflect the transition of MPD1 and MPTT transition activity to our marketing partners. EPGL is essentially returning to "start-up" mode under the major development projects underway. Our future has never been brighter than it is right now in our opinion and we are working everyday to bring very significant value to our shareholders. We are also working to enlighten the investment community at large, to the incredible activities we are up to lately, leading giants, as soon as we possibly can. EPGL MEMS is leading!
EPGL is leading the giants with cutting edge technology. "We're at a new beginning and ground floor for EPGL with our recent reconfiguration of focus on the most significant opportunities. We think our most loyal shareholders will be amazed and excited about what they are part of." -Michael Hayes, President, EPGL.
12. Daaaaamn! So, that answered that! Amazing stuff! But now I have another question. Why are they still technically called EPGL Global Communications and not EPGL Medical Sciences? I've heard here and there that they were supposed to change their name a while ago.
Because the former company, EPGL Global Communications, whom was a registered company with the SEC, de-registered back in 2009 as their troubles mounted. It is EPGL's plan to officially change their name when they re-register with the SEC. Which they had planned to do when they finished up the house keeping from the liquidation process. The former company made quite a mess of the ticker. Then things began to shift towards BioMEMs and the possibility of being bought out dramatically increased. EPGL put off re-registering, simply put, because they may never have to. Why go through all of that if you get bought out? Right now, EPGL is waiting to see what happens. Once the dust settles they have more clear picture of the future of the company, they will re-register and be formerly recognized as 'EPGL Medical Sciences' by the powers that be, if need be.
13. Well, my mind has just been blown! This is all just plain awesome! Thanks a ton. I will continue with my DD. I look forward to becoming a long term holder of this. Before you go, anything else I should look at?
Sure. Check out this timeline since EPGL was formed. It will show their accomplishments to date and hopefully answer any other questions you might have. Cheers and good luck.
June 27th, 2012
EP Global Communications, Inc. Achieves Shareholder Approval for Restructuring and Signs Definitive Restructuring Agreement
Company Becomes Medical Device Manufacturer and Marketer
This is a MUST read
July 11th, 2012
EP Global Communications, Inc., Announces the Appointment of Corey W. Hunter M.D. as Company Medical Director and Chairman of Scientific Advisory Board. Respected Pain Physician Headed a Team of Scientists at NYU for Early Findings on the FDA Cleared MPDD Device. Will Now Lead Device to the U.S. and International Healthcare Markets.
All the toxic debt has now been eliminated and there will be no unscrupulous dumping of shares into the market as service to debt ever again. The restructuring partners will never consider such a financing arrangement in the future and will not allow that predicament to occur to the Company or its shareholders again. In contrast, the restructuring partners of the Company are committed to growing the Company and shareholder value significantly for the long term.
Corey Hunter, M.D. & Elimination of Toxic Debt
July 26th, 2012
EP Global Communications, Inc. Announces Friday July 27, 2012 as Effective Date for Approved Reverse Split
EP Global Communications, Inc., announces that FINRA has set Friday July 27, 2012 as the market effective date for the 10:1 reverse split of common outstanding shares. The Company shareholders previously approved the reverse split on June 8, 2012.
As a result, the Company will eliminate 100% of major debt and effectuate a new direction into the medical device manufacturing and marketing sector.
August 21st, 2012
EPGL Launches Twitter account and begins to update shareholders regularly with tweets and Q&A sessions
Twitter Page
August 30th, 2012
EP Global Communications, Inc., Announces First Orders for MPDD Medical Device and the Addition of Eric Lee M.D. M.A. to Medical Team
September 5th, 2012
EPGL Med conducts it’s 1st Q&A session for investors via Twitter. They discuss the MPDD along with it’s potential, and company plans for the future, etc, etc.
Investor Q&A #1
September 24th, 2012
EP Global Communications, Inc. Lands One of the World's Leading Biomedical Engineers.
David T. Markus holds a Ph.D. in Biomedical Engineering and a MS in Electrical Engineering with an emphasis in MEMS Microelectronics and Biomedical. The worldwide market for Bio-MEMS medical technology is estimated to grow into hundreds of billions of dollars over the next several years in healthcare as well as other technological markets. The Company plans to aggressively pursue new technology opportunities in this field of medical technology.
EPGL hires David T. Markus Ph.D
September 26th, 2012
EPGL Launches Website
EPGL Website
September 26th, 2012
EPGL Med conducts it’s 2nd Q&A session via Twitter for investors. They discuss fundamentals, management, the MPDD, etc, etc.
Twitter page detailing Investor Q&A #2
October 9th, 2012
Ryan M. Stellar M.E. B.E. joins Corey Hunter M.D., Eric Lee, M.D.M.A. and David T. Markus Ph.D. on the EPGL Team.
EPGL Team
October 17th, 2012
EPGL Med conducts 3rd Q&A session via Twitter with investors. They discuss new staff, sales goals, etc, etc.
Twitter page detailing Investor Q&A #3
November 28th, 2012
EP Global Communications, Inc. Releases Dramatically Improved Balance Sheet After Restructuring, Announces New Assets
For the First Time in Two Years, Company Begins to Report Again and Move Up OTC Tiers on the Way to Full SEC Reporting in 2013
EPGL Begins Reporting. Sheds 'No Info Status'
November 28th, 2012
EPGL is announcing today for the first time, it has acquired significant new assets other than the MPDD device rights, in the BioMEMS arena. BioMEMS will be a major focus for the Company going forward as previously announced.
BioMEMS devices are as important to the future of medicine as microprocessors were to the computer revolution at the end of the last century. BioMEMS is a science that includes more than simply finding biomedical applications for microelectromechanical systems devices. It represents an expansion into a host of new polymer materials, microfluidic physics, surface chemistries and their modification, 'soft' fabrication techniques, biocompatibility, and cost-effective solutions to biomedical problems. It brings together the creative talents of electrical, mechanical, optical, and chemical engineers, materials specialists, clinical laboratory scientists, and physicians. BioMEMS devices are the platform upon which nanomedicine will be delivered.
EPGL Enters bioMEMS Arena
November 28th, 2012
EPGL Med conducts it’s 4th Q&A session via Twitter with investors. They talk about entering the bioMEMS industry, getting to current status, etc, etc.
Investor Q&A #4
December 31st, 2012
EPGL Med files EP Global Communication's Annual Reports containing Income Statements and Balance Statements from 2010 and 2011
Balance Statement 2010
Income Statement 2010
Balance Statement 2011
Income Statement 2011
December 31st, 2012
EPGL Med files it's Articles of Incorporation
Articles of Incorporation
December 31st, 2012
EPGL Med files it's Bylaws
Bylaws
January 4th, 2013
EPGL Med conducts it’s 5th Q& with investors via Twitter. They reaffirms their goal of meeting all of the requirements of uplisting to the OTCQX U.S, the company’s share structure, etc, etc
Investor Q&A #5
January 4th, 2013
Via Twitter, EPGL Med selects a Singapore based firm for its Asia distribution. This, among other news will be detailed in January 25, 2013 announcements.
@EPGLMed
January 8th, 2013
EPGL Med files it's 2012 Annual Report, Initial Company Information and Disclosure Statement
*Highlights
Quote:
Sharestructure
5,000,000,000 Authorized Common
4,668,000,000 Outstanding
499,161,167 Freely trading
The Company plans to manufacture, market and develop several new medical devices. Over the next 12 months, the company will seek strategic partners in equity finance, manufacturing and distribution to achieve these objectives.
The Company will not restructure again or propose any further reverse splits now or in the future. The Company believes it has more than adequate cash resources to see operations through the next 12 months.
Chronic back pain treatment in the United States alone is estimated to cost nearly $100 billion dollars annually. Utilizing recent Bureau of Labor Statistics data an estimate for the potential U.S. market for the MPDD is $2 billion and an additional $2.5 billion
globally, for a total potential market of $4.5 billion.
The Company projects that within 6 months of market launch, sales have the potential to exceed 2000 units per month worldwide and generating $10 million dollars per month.
2012 Annual Report
January 8th, 2013
EPGL Med files Supplemental Information to the OTC.
Statement of Cash Flow For the 12 Months Ended December 31, 2010.
2010 Cash Flow of Former Company
January 8th, 2013
EPGL Med files Supplemental Information to the OTC.
Statement of Cash Flow For the 12 Months Ended December 31, 2011.
2011 of Former Company
January 10th, 2013
EPGL files it's Attorney Letter to the OTC, meeting the requirements needed to be uplisted from 'Limited Information' to 'Current Status'.
Attorney Letter to OTC
January 10th, 2013
EPGL Med Files Supplemental Information - Financial Report Year to Date as of December 31,2012 - Amended
2012 Annual Report Ammendment
January 11th, 2013
EPGL is Uplisted to OTC Current Information!
January 11th, 2013
EPGL announces that all EPGL restricted shares were issued late in year 2012 with 99% of them being issued after December 20, 2012. The controlling shareholders, PWC/AJW Qualified/Hayes have all committed to long term growth of EPGL and will not enter any agreements where restricted shares can be "dumped" into the market. If any shareholder is not clear on this, they can contact EPGL investor relations for further clarification.
Contact Brady Peterson at EPGL Investor Relations
January 25th, 2013
EPGLMed Issues Press Release.
The PR highlights EPGL’s success at landing a worldwide distribution deal in Singapore and a manufacturing deal in San Diego. Furthermore, they named March 29th, 2013 as the date they will announce when the MPDD’s get officially released. Also highlighted are the 6 new devices that EPGL is currently developing within the BioMems field.
Lastly, they announced new team members, Noah T. Kaufman, M.D. as Vice President of Emergency Medicine Innovations, Mark Rea as Innovations Advisor and Reid H. Erickson as Financial Partnership Strategy Advisor.
Worldwide Distribution Channel & Manufacturing Deal Announced along with New BioMems Devices, etc, etc
January 25th, 2013
EPGL conducts it’s first ever conference call for shareholders.
Michael Hayes talks about share structure and EPGL’s & PwC’s commitment to creating shareholder value, company goals of becoming a 50 Billion dollar company listed on the Nasdaq or NYSE, etc, etc. Listen to it. Starts 0:35.
Highlights include the Restricted Share Structure and how and why those shares will never enter the float.
Introductions of Staff.
Long term goals of the company.
etc, etc, etc. Just listen to the thing!
EPGL Conference Call
January 30th, 2013
In accordance with the 2012 Restructuring Agreement, EPGL has acquired the option and right of first refusal to all AJW / Pricewaterhouse Coopers controlled holdings. This includes up to 2.25 billion of RESRICTED common shares.
EPGL Granted 1st refusal of AJW's 2.25 Billion shares!
February 22, 2013
EPGL Receives First Physician Review of MPDD Device
Quote:
“As you know I have had the opportunity to purchase and implement the Muscle Pain Detection Device into my pain management practice. I just wanted to give you some feedback as to my experience with the device, which up to this point has been quite encouraging..........cont”
Physician Review of the MPDD
February 25th, 2013
EP Global Communications, Inc. Announces Major Shareholder Update and Events Coming for March 2013. New Patents Being Filed and First Medical Device Release Among Topics
First, the Company announces that up to 12 new medical device patents will be filed in the month of March, 2013......
Second, the MPDD device will be released on March 25, 2013......
Third, the MPTT (Muscle Pain Trigger-Point Treatment) is being put on a track to be released by December, 2013 pending FDA 510k approval..........
Fourth, DTC restrictions on some brokers are expected to be lifted at any moment. The Company counsel has filed all requisite documents and all brokers should have access to EPGL stock electronic deposit services, shortly......
Fifth, as shareholders know, the Company has achieved Current Information status with OTC Markets. Now, the Company plans to graduate the EPGL symbol to OTCQX by end of year 2013. Following that movement, the next goal will be to bring the Company to NASDAQ or NYSE sometime in 2014.....
Shareholder Update
February 25, 2013
EPGL Conducts it’s 6th Investor Q&A via Twitter. They discuss the timetable in up listing to the OTCQX, the DTC restrictions being lifted, product development, and much, much more.
Investor Q&A #6
March 21st, 2013
EP Global Communications, Inc, EPGL Medical Begins Selling MPDD Devices, Singapore Distributor Secures First 1,000 Units Off Assembly Line
EPGL Seeing High Demand Beginning for First New Medical Device Released in US and International Markets.
MPDD Hits the Market!
EP Global Communications, Inc. (the Company), is pleased to announce that the Company has begun selling MPDD units both in the US Market and Internationally. The exclusive Singapore distributor has secured the first 1,000 units to come off the assembly line. In addition, the Company is simultaneously engaging the top 20 international markets throughout the world in addition to the United States.
April 2nd, 2013
EPGL conducts it’s second Conference call for shareholders.
Conference Call
April 11th, 2013
Google Glass to be Integrated by Medical Device Maker EPGL Med and EP Global Communications, Inc.
Company to be Among the First to Develop Medical Device Applications for Newest Smart Technology
EPGL to Implement Google Glass Tech
EPGL will be among the first Medical Device Makers to Implement Google Glass technology and the API Mirror platform for use with its medical devices. EPGL Medical, a new medical device maker specializing in advanced technology for innovative hand-held medical devices, has several new devices in development under direction of David T. Markus Ph.D., which are being developed with the latest smart platforms in mind.
Also, In addition to integrating smart technology such as Google Glass, EPGL Medical now has a "secret weapon" medical device technology advancement which no other medical device company has. This single technology will be the catalyst for dozens of new medical device technologies to be produced or licensed by the Company. The Company is in the process of filing more than 50 patents to protect this unique and valuable innovation.
April 11th, 2013
EPGL announces that is in talks to have a leading East Coast PR firm to dramatically increase exposure to the broader investment community. This will be put in place by end of April 2013 for the purpose of educating investors worldwide of the undervalued nature of EPGL presently.
EPGL Twitter
April 18th, 2013
EPGL announces that it has established Distribution in the 20 Global Markets and is working on establishing distribution with the Middle East to New Zealand.
EPGL Twitter
April 22nd, 2013
New BioMEMS Medical Device Platform "TopSpin" to Be Revealed by EPGL Medical and EP Global Communications, Inc., During "7 Days in April" Conference Call Series
David T. Markus Ph.D. Will Host Live Conference Call Series Starting April 24 through April 30, 2013.
7 Days of April Event!
As one of the top BioMEMS engineers in the world, Dr. Markus along with others, will unveil the importance and value of EPGL's new BioMEMS device platform in today's medical marketplace. The new technology stands to spawn potentially dozens of new medical devices, giving doctors innovative new tools for diagnosis and treatment.
May 16th, 2013
EPGL Files 1st Quarter Report along with
Q1 Balance Sheet, Income Statement & Cash Flow Statement
Q1 Balance Sheet, Income Statement & Cash Flow Statement
Cash & cash Equivilants: $12,868,500
Intellectual Property: $1,088,602,000
Total assets: $1,257,653,000 Q1 Report
Share Structure as of March 31st, 2013
5 Billion Authorized Common
4,668,229,167 Outstanding
4,169,068,000 Restricted
499,161,167 Tradable Float
May 20th, 2013
Article Published By Major Medical Device Magazine, MD-DI
Will EPGL's TopSpin Serve Up the Next Generation of Medical Devices?
A former DARPA scientist and a device startup want to change medical devices forever using bioMEMS
MD-DI Article
June 14th, 2013
Review Published by Manhattan Sports & Spine Medicine regarding MPDD
New Technology Promises Hope for Chronic Muscle Pain.
Manhattan Sports & Spine Medicine review of MPDD
June 18th, 2013
EPGL Medical Unveils New Devices and Intellectual Property Under EP Global Communications, Inc. Ownership
Advanced Device Prototypes on the Way Along with FDA 510k and PMA Applications.
New Devices and Intellectual Property
1. A new advanced ablation device for nerve pain treatment in the back.
2. A new advanced ablation device for nerve treatment of Facial Glabballar Frowning.
3. A new advanced device for elimination of facial wrinkles.
4. A new advanced Epidural device.
5. A new advanced power source for TopSpin medical devices.
6. A new and promising device for treatment of Retinitis Pigmentosa
7. A new and promising device for treatment of Macular Degeneration
8. A new and promising treatment for Hearing Loss
9. A new more accurate treatment for trigger points in the muscles (MPTT)
10. A new advanced device for treatment of prostate tumors.
11. A new advanced endoscopic device.
12. A new advanced device for delivery of micron sized drug payloads.
13. A new advanced device for delivery of micro mechanical devices into the body.
14. A new advanced device for biopsy.
15. A new advanced device for stem cell treatment delivery.
16. A new advanced contact lens device.
June 25th, 2013
DTCC Chill Lift is Authorized
Company Will Immediately Move to File with SEC for Up-Listing EPGL Ticker
DTCC Chill Lift is Authorized
“EPGL is pleased to announce that DTCC counsel has confirmed their authorization for removal of the DTCC Chill on EPGL ticker. The Company is also announcing that it will immediately move to file SEC forms for up-listing the Company to a higher stock exchange.”
July 29th, 2013
EPGL Medical Invents Self Powered Contact Lenses for Medical and Consumer Applications.
"Using cutting edge technology, EPGL has invented a self perpetuating power source for lenses which does not require external energy such as RF," said David Markus PhD. "The market for contact lenses as information data display devices is just beginning and will be a natural extension of new wearable data devices such as Google Glass." EPGL intends to license the new technology to companies who are developing data display for contact lenses.
Invention Powers Contact Lenses Day or Night from Within
August 7, 2013
EPGL Medical Invents New Cell Regeneration Technology For Eye Disease
EPGL engineers have invented a new device for the purpose of treating serious eye diseases such as macular degeneration and retinitis pigmentosa. The technology emits low intensity pulse ultrasound into the eye for the purpose of regeneration of damaged cells and to possibly arrest the degeneration of existing healthy cells within the macula and the entire retina.
"The technology has proven to be very effective in recent research. We now have the ability to use MEMS to put the technology into the micro size environment for contact lenses.
EPGL Medical Invents New Cell Regeneration Technology For Eye Disease
August 12, 2013
EPGL Medical Invents Smart Epidural Needle, Nerve Ablation And Trigger Point Treatment Devices
New Smart Medical Devices Will Give Physicians Advanced Situational Awareness During Critical Procedures.
"EPGL is a company that is amassing advanced device technologies at a rapid pace and will make its mark with development of smarter medical devices." said David T. Markus PhD. "We have the advantage in advanced MEMS technology and this is the field that will revolutionize medicine in the next several years. EPGL shareholders are in a very special company at a special time."
EPGL Medical Invents Smart Epidural Needle, Nerve Ablation And Trigger Point Treatment Devices
August 15, 2013
EPGL files 2nd Quarter 2013 Report . April 1st thru June 30th.
2nd Quarter Report
August 15, 2013
EPGL Files 2nd Quarter 2013 Financial Statements
Cash Balance at Beg of Period
$12,868,000.50
Cash and Cash Equivalents June 30, 2013
$15,690,000.50
Increase of $2,822,000
EPGL 2nd Quarter 2013 Finacials
September 15th, 2013
AJW Investor Update
AJW Investor Update
November 15th, 2013
Epgl Files 3rd Quarter 2013 Financial Statements.
Cash and cash equivalents: $19,332,500
Total Assets: $1,785,321,500
Supplemental Information
3rd Quarter 2013 Financials
December 16th, 2013
EPGL Technology Selected by Major Corporation for Development
In a first for the company, one of EPGL's advanced technologies has been selected by a multi-billion dollar, NYSE publicly traded industry leader for development and integration into new products. "This is the biggest development for our company in its history," said David T. Markus PhD.”
EPGL Technology Selected by Major Corporation for Development
January 14th, 2014
Pricewaterhouse Coopers, Ian Stokoe, pens letter confirming the deal EPGL made with a muti-billion dollar NYSE company.
......"In my view, this is a significant milestone and, as a major shareholder, I look forward to the future success of EPGL."
PWC Letter
February 11, 2014
EPGL Developing Wearable Tech
EP Global Communications, Inc., (OTC Ticker EPGL) announces that as of fourth quarter 2013, EPGL has focused 100% on development of smart wearable technology. Because of recent developments and opportunities before the Company, EPGL has now established itself as an early player in the growing field. "Leading industry insiders believe wearable smart technology will be as large as the smart phone revolution. We agree with that," says David Markus Ph.D. while referencing Wired Magazine's January 2014 Cover Story. "Our unique technology and know-how, puts EPGL in demand. We've talked about this in our announcements since mid-2013."
"EPGL is very fortunate to be among a few serious players right now, who are pioneering this technology. These are visionary companies and people at the top of their field. We're swimming with the big fish and nobody knows who we are just yet," said Michael Hayes, Company President. "But they will in due time."
EPGL Developing Wearable Tech
February 20th, 2014
Q4 2013 Quarterly Report
February 23rd, 2014
Supplemental Information Ammended Q4 Financials
March 18th, 2014
EPGL Shareholder Update: Meetings in Bay Area Recently, Went Well. EPGL is Positioned with Industry Leaders on Innovation of Wearables.
April 15th, 2014
EPGL Shareholder update: EPGL Announced Advanced Contact Lens Technology in August of 2013. Since then our technology and know how has caught the eyes of the world's leading companies in the field. Now, EPGL is on the forefront of innovating the technology and EPGL MEMS will be inside the world's most advanced contact lenses as we move into this new revolution of smart, wearable technology.
EPGL technologies are on the cutting edge and in demand. We believe current dedicated shareholders will be proven to be "visionary".
May 15th, 2014
EPGL Shareholder Update: As EPGL has now transitioned to focus on a major MEMS technology development, the Company is transferring all MPD1 and MPTT future development and marketing to our distribution partners in Asia and the United States. As such, the MPD1 activity which has been stalled since 4th Quarter 2013, will begin to have new life in 2014 and our partners will pick up the ball and aggressively pursue sales of MPD1 starting 3rd Quarter 2014. As a result of this, EPGL will be enabled to focus 100% on major development projects which are important to the Company while reinvigorating the MPD1 and MPTT projects under our partners efforts. Q1 2014 financials, to be released within 72 hours, will reflect the transition of MPD1 and MPTT transition activity to our marketing partners. EPGL is essentially returning to "start-up" mode under the major development projects underway. Our future has never been brighter than it is right now in our opinion and we are working everyday to bring very significant value to our shareholders. We are also working to enlighten the investment community at large, to the incredible activities we are up to lately, leading giants, as soon as we possibly can. EPGL MEMS is leading!
EPGL is leading the giants with cutting edge technology. "We're at a new beginning and ground floor for EPGL with our recent reconfiguration of focus on the most significant opportunities. We think our most loyal shareholders will be amazed and excited about what they are part of." -Michael Hayes, President, EPGL.
May 18th, 2014
Q1 2014Balance Sheet, Income Statement & Cash Flow Statement
May 30th, 2014
EPGL Shareholder Update: EPGL achieves Phase 2 of advanced technology development project. Another milestone and now closer to revelation for long shareholders.
June 19th, 2014
EPGL Shareholder Update: EPGL is leading the advance MEMS technology design and product development for one of the largest companies in its field. The relationship has expanded under phase two and involves co -ownership of product technologies under development. All EPGL technologies are involved. The technology and products will be manufactured by the NYSE company branded under its name and distributed worldwide, by that Company and others affiliated. EPGL's role is that of research, design, development and ownership of the various technology applications. We are developing an "open source" platform with this company to enable many other organizations and entities to create new products with a new platform. EPGL shareholders should realize that this situation is very real and developing. We are getting very much closer to the time we can reveal all. This will happen no later than August 29, 2014.
EPGL is unlike any other OTC Pink Sheet company at this time. Shareholders are right to be excited about our future. By the way,EPGL and our partners could make an announcement sooner that August 29, 2014.
June 30th, 2014
Q1 2014 Disclosure Statement Update
July 17th, 2014
EPGL Shareholder Update: Google took glucose lens as far as they could. Now the "X" man is an ex-man. Enter Novartis to try to figure it out. But Novartis reached out to EPGL not long ago. So whose technology will dominate coming smart lens revolution? EPGL is leading giants and focused on new smart lens technologies which will enable mass marketing in both health and consumer electronics well into the future. Many companies and institutions stand to be enabled by our work. EPGL is working with the best in the business and more is to come by August 29, 2014. EPGL shareholders should be excited at the prospects.
July 18th, 2014
EPGL Shareholder Update: It can now be revealed that both Novartis and Google reached out to our development team members in recent weeks and months. This fact should be a clue to the gravity and know-how of our team in both BioMEMS and manufacturing of smart contact lenses. We intend to set the industry's standard with our enabling technology. Who are we teamed up with? Who will ultimately include EPGL originated technology.
The following is lengthy mock Q&A for a new investor that wants to learn more. It is a very long post, but explains a ton. At the end is the timeline for EPGL since it's inception back in the summer of 2012.
EPGL Medical Sciences.
www.epglmed.com
1. What is EPGL???
Epgl Global Communications, aka EPGL Medical Sciences, is a new biomedical device marketing company. The Company is currently working to invent and develop cutting edge medical device technology products including biomedical devices which utilize Bio-Micro-Electro Mechanical Systems technology (Bio-MEMS).
2. Bio-MEMS????
Yes, EPGL is currently focused and centered around the BioMEM field. BioMEMS are micro-electro-mechanical systems. Mechanical parts and microfabrication technologies made suitable for biological applications. A broad definition for bio-MEMS can be used to refer to the science and technology of operating at the microscale for biological and biomedical applications, which may or may not include any electronic or mechanical functions.
Bio-MEMS is one of the fastest growing and promising new frontiers in medical technology today with possibilities in both medical diagnostic and treatment applications.
http://en.wikipedia.org/wiki/Bio-MEMS
Currently EPGL has as it's chief scientist, former DARPA and Raytheon Engineer/Inventor and expert BioMEM scientist, Dr. David Markus, in which he and EPGL laid plans to develop some of the smartest and tech saavy products ever seen.
September 24th, 2012
EP Global Communications, Inc. Lands One of the World's Leading Biomedical Engineers.
David T. Markus holds a Ph.D. in Biomedical Engineering and a MS in Electrical Engineering with an emphasis in MEMS Microelectronics and Biomedical. The worldwide market for Bio-MEMS medical technology is estimated to grow into hundreds of billions of dollars over the next several years in healthcare as well as other technological markets. The Company plans to aggressively pursue new technology opportunities in this field of medical technology.
EPGL hires David T. Markus Ph.D
With the hiring of Dr. David Markus, EPGL exposed itself to the amazing world of BioMem technology. With the worlds leading scientist and patent holder of such technology, EPGL explored the idea of branching into that field. They came up with platform based technology coded 'Top Spin' that could put EPGL at the top of the food chain.
June 18th, 2013
EPGL Medical Unveils New Devices and Intellectual Property Under EP Global Communications, Inc. Ownership
Advanced Device Prototypes on the Way Along with FDA 510k and PMA Applications.
New Devices and Intellectual Property
1. A new advanced ablation device for nerve pain treatment in the back.
2. A new advanced ablation device for nerve treatment of Facial Glabballar Frowning.
3. A new advanced device for elimination of facial wrinkles.
4. A new advanced Epidural device.
5. A new advanced power source for TopSpin medical devices.
6. A new and promising device for treatment of Retinitis Pigmentosa
7. A new and promising device for treatment of Macular Degeneration
8. A new and promising treatment for Hearing Loss
9. A new more accurate treatment for trigger points in the muscles (MPTT)
10. A new advanced device for treatment of prostate tumors.
11. A new advanced endoscopic device.
12. A new advanced device for delivery of micron sized drug payloads.
13. A new advanced device for delivery of micro mechanical devices into the body.
14. A new advanced device for biopsy.
15. A new advanced device for stem cell treatment delivery.
16. A new advanced contact lens device.
Feel free to check out these articles based upon Dr. Markus and EPGL's technology.
Will EPGL's TopSpin Serve Up the Next Generation of Medical Devices?
Company Designs MEMS-Based Energy Harvester for Contact Lenses
3. A smart contact lens? Sounds f'n cool as hell!
It sure is! Checkout these two PR's regarding such work, as well as other actions.
EPGL Medical Invents Self Powered Contact Lenses for Medical and Consumer Applications
EPGL Medical Invents New Cell Regeneration Technology For Eye Disease
Then in December of 2013, they were selected by a multi-billion dollar NYSE company to integrate EPGL's tech into theirs.
December 16th, 2013
EPGL Technology Selected by Major Corporation for Development
In a first for the company, one of EPGL's advanced technologies has been selected by a multi-billion dollar, NYSE publicly traded industry leader for development and integration into new products. "This is the biggest development for our company in its history," said David T. Markus PhD.”
EPGL Technology Selected by Major Corporation for Development
4. Wow! Who's the company?
Due to a non-disclosure agreement (NDA) between the company and EPGL, which is a common business practice with these types of deals, EPGL is currently unable to divulge who the company is or the terms of the deal. But the information is going to be released soon.
Since then investors have been speculating on who the company is and what impact it will have on EPGL.
Then EPGL announced the following"
Quote:
EPGL Announced Advanced Contact Lens Technology in August of 2013. Since then our technology and know how has caught the eyes of the world's leading companies in the field. Now, EPGL is on the forefront of innovating the technology and EPGL MEMS will be inside the world's most advanced contact lenses as we move into this new revolution of smart, wearable technology.
EPGL technologies are on the cutting edge and in demand. We believe current dedicated shareholders will be proven to be "visionary".
That pretty much summed up that they are working on a smart contact lens. Then they soon followed up that announcement with:
Quote:
EPGL is leading the advance MEMS technology design and product development for one of the largest companies in its field. The relationship has expanded under phase two and involves co -ownership of product technologies under development. All EPGL technologies are involved. The technology and products will be manufactured by the NYSE company branded under its name and distributed worldwide, by that Company and others affiliated. EPGL's role is that of research, design, development and ownership of the various technology applications. We are developing an "open source" platform with this company to enable many other organizations and entities to create new products with a new platform. EPGL shareholders should realize that this situation is very real and developing. We are getting very much closer to the time we can reveal all. This will happen no later than August 29, 2014.
EPGL is unlike any other OTC Pink Sheet company at this time. Shareholders are right to be excited about our future. By the way,EPGL and our partners could make an announcement sooner that August 29, 2014.
5. Doesn't Google want to do this???!!! Or some other behemoth? I read somewhere that Google was trying to make a smart contact lens.
They all want to, but none of them, other than EPGL, has the technology to make it all work. It's still very 'new'. But Dr. Markus has been working on it for the past 2+ decades. Google made a big deal a few months ago about how they were developing a smart contact lens. However, to their dismay, they failed at being able to make it work and have reached out to EPGL for help, as well as contact lens giant, Novartis.
6. Hot damn! So, is it possible that the mystery company could be Google?
EPGL summed that up best on July 18th, 2014 when they updated shareholders.
Quote:
It can now be revealed that both Novartis and Google reached out to our development team members in recent weeks and months. This fact should be a clue to the gravity and know-how of our team in both BioMEMS and manufacturing of smart contact lenses. We intend to set the industry's standard with our enabling technology. Who are we teamed up with? Who will ultimately include EPGL originated technology.
7. Holy cow! Well that explains why the stock has been hot as of late. I really want to invest in this. But at the end of the day, this is still a Pink Sheet Company. How am I to believe what I am seeing unfold? Aren't all pink sheet companies bogus in one way or another. I've been fooled many time over in this arena and have lost thousands of dollars trusting Pink Sheet Companies.
Good question. I too, have lost thousands in this arena. The one thing that those company's don't have, and what EPGL has....is ACCOUNTABILITY. Comes down to logical thinking. This will be a bit lengthy, but its a good deduction of why you should separate EPGL when thinking of your typical Pink Sheet Company.
Typical pinksheet stories have companies formed from shells after massive R/S's take out all previous existing shareholders. 1/1000 and up. EPGL executed a 1/10, during it's positive restructuring, 2 years ago which kept all existing shareholders in. The majority of those investors have stayed and added more shares from .001 to where we are now. Despite fear mongering by a few, those investors, including myself, have increased our portfolio value by 5-6 figures by owning EPGL over the past 2 years. No other stock has ever given me a 3600% increase in 2 years. Why did I stay in? I applied simple logic.
Typical Pinksheet stories have companies that are created by a shady financier and their seed shareholders, sponsored by corrupt individual lawyers and corrupt accountants whom the majority of which are listed on the OTC's main page. EPGL was created by PwC, one of the most prestigious and reputable accounting firms on the planet, trusted by and given the opportunity by the federal courts, and monitored by the SEC, as part of a liquidation process whereas, EPGL was to be restructured and become a medical device company, with the capabilities of being a profitable company, wherein, the value of such a company will eventually lead to PwC recouping lost capital for defrauded investors from a corrupt hedge fund.
Typical pinksheet stories have companies that have no accountability. EPGL and PwC are accountable to the investors PwC needs to assist and retrieve funds for as well as the Federal Courts that put PwC in charge. Basically, put, if EPGL is lying, then that means PWC is in cahoots with it. You think that's a possibility? Go to this site and see if you think PwC is scamming the investors it's helping.
September 15th, 2013
AJW Investor Update
AJW Investor Update
Typical pinksheet companies have promoters that pump the stock. The promoters, and or the agencies that actually retain them, are often paid in stock for their services, or will front load, i.e. buy stock out of the market in advance of a coming 'Pump & Dump' campaign. And of course, they definitely know when a Pump & Dump campaign will launch and may be intimately involved in the timing and content of press releases. EPGL does not have any such promoters, nor has there been a P&D after nearly 2 years of being in business.
Typical Pinksheet stories are loaded with toxic debt. This is simple. EPGL has $0.00 toxic debt.
Typical Pinksheet stories dilute shares immediately and often as possible. EPGL has not diluted one single share in nearly 2 years of operations. nor have they diluted since their shares have become unrestricted.
Typical Pinksheet stories don't have a product. EPGL, although the MPDD/MPTT has been given to their partners to market and produce, they own the patent rights and will make royalties off of the sales. The devices are proven to be real as they have been demonstrated on national news shows, etc, etc.
Typical Pinksheet stories don't have world renowned scientists working for them. Dr. David Markus is well known throughout his field of expertise. Having worked with DARPA, Raytheon, etc, etc, his reputation speaks for itself. Simple, elementary logic states that he will not damage it by belonging to a corrupt company or a company that can't see things though. Given the well documented work that Dr. David Markus has been a part of over the past decades, what he is producing as the lead scientist for EPGL, it is proof enough that their tech is more than believable and well worth the risk of investing in the company.
Typical Pinksheet stories don't have billion dollar NYSE companies partnering up with them. Granted we have no proof that a company did with EPGL because they had to sign an NDA agreement, but it would be completely illogical for both PwC and EPGL to lie about it given whats at stake. There is just no proof or logic to support any claim that such a deal does not exist. It would be foolish for any investor to think so.
I could go on and on and on and on and on. You get it.
8. Wow. I never looked at it like that before. But if I may, I've noticed thru my initial DD, that EPGL is not registered with the SEC. I've heard that companyies that de-registered never re-register. Does that mean that EPGL will never re-register? And what about the name change I've heard about?
It does not mean that at all. This can be confusing. It's important you focus when reading this. And use logic when thinking about that your question.
Very rarely, if ever, does a company that de-registers with the SEC, re-register. That's because after that company de-registers, it goes BK and disappears. If it doesn't go BK, it remains the same company, with the same product and the same problems that caused it to de-register in the first place. No product, tons of toxic debt, bad management, etc, etc. With no chance to realistically create revenue. It then becomes a shell.
EPGL, on the other hand, is an entirely new company! It is not the same company that had the name and ticker that de-registered! The only similarity it has with the former company is the name and the ticker. EPGL has new management, zero debt, a pipeline that is going to take the lead in a brand new market place, a billion dollar NYSE company funding EPGL's R&D, etc, etc. It's a new company that inherited only the name and the ticker. That's all. You understand? Going by the logic, "EPGL de-registered with the SEC. No company has ever re-registered with the SEC after it de-registered. Therefore, EPGL will not re-register" is an extremely illogical and reckless way to deduce things. EPGL Medical Sciences...the company you see before you, never de-registered because it was never registered in the first place. Once you read between the lines, everything becomes clear and obvious.
It is EPGL's plan to officially change their name when they re-register with the SEC. Which they had planned to do when they finished up the house keeping from the liquidation process. The former company made quite a mess of the ticker. Then things began to shift towards BioMEMs and the possibility of being bought out dramatically increased. EPGL put off re-registering simply put because they may never have to. Why go through all of that if you get bought out? Right now, EPGL is waiting to see what happens. Once the dust settles they will re-register and be formerly recognized as 'EPGL Medical Sciences' by the powers that be.
9. Yeah, I get it. Seems logical!! Thanks!!! So, Back to the NYSE company partnering up with EPGL. How do you think it will go down? I know you can only speculate, but I know nothing of these types of deals. Can you speculate for me? Give me an idea of what is possible???
Sure, I'll try and explain it way I personally feel the deal will go down. The deal in my eyes, will most likely work like this.....
The way it is most likely going to work is that the NYSE partner is going to be handling all of EPGL's operating costs. R&D, manufacturing, etc, etc. In simple terms, EPGL will work as the NYSE Company's R&D Department. All expenses paid and 50% of all revenues generated.
The NYSE Company will most likely be handling of all of the R&D costs associated with making the technologies/products a reality. from the FDA 501k's, Patent processing, the NYSE Company's distribution channels, Legal Issues, etc, etc. The NYSE company will be absorbing the majority of risk and will be giving EPGL a good cut.
Also remember, EPGL's tech is not the product. EPGL's specific tech makes the product work. This company wants to integrate all of EPGL's tech into their products. Then, if another company comes along and wants EPGL's tech integrated into their product, the NYSE Company gets a 50% piece of that. It's all a win-win situation. Additionally, having everything under the NYSE Company's name, a 7 billion dollar proven industry giant, gives the tech added legitemacy and helps speed things along and create other opportunities.
Again, EPGL will be spending next to nothing, while it works to integrate it's tech into the NYSE's Company's products. Then, EPGL gets co-ownership of the specific product and half the revenues that will be generated.
It would appear that there won't be a buyout simply because the NYSE Company, at this current time, can't afford the number EPGL/PwC was likely asking. Doesn't rule it out in the future, once the revenues start pouring in. You can bet that the NYSE Company will have 1st right of refusal when it does come to EPGL being bought out.
All and all, this is all just my theory. Won't know for sure until the full details are actually released. But in reality, it is the most likely way things are to be done.
10. Awesome! Thanks. So as you mentioned above, regarding EPGL's product, its not so much that EPGL's tech is the product, but more so that EPGL's tech is what gives the product life? Makes the product function?
Yes. In layman's terms. And it opens up EPGL to other company's to partner up with as well that have a product in BioMEM's they want to have produced.
11. All of this is very interesting. One more thing, if I may. I read that EPGL had a device called the MPDD and were close to finishing up development on the MPTT. What ever became of those devices?
Good question. When EPGL first started out 2 years ago, the MPDD was their initial product. A device that detected the true source of back pain. The MPTT was a dveice being developed that could then treat that pain. Of course, like all start up bio techs, there is an evolution that occurs. As Dr. Markus' BioMEM platform started to advance, it became clear to EPGL that the road they should take should center more on BioMEMS and that they should work to strengthen their position in that market, as they are frontrunners. So, EPGL reconfigured their business plan to better suit a more profitable and more esteemed plan of action in that field. EPGL's distributor took over all aspects of the MPDD and will take the lead in marketing it and selling it, etc. It will also take the lead in dealing with the MPTT. EPGL will sit back and collect royalties, increasing it's revenue in addition to the potential revenue it will incur from it's bioMEM tech.
From EPGL's CEO Michael Hayes regarding this process:
Quote:
As EPGL has now transitioned to focus on a major MEMS technology development, the Company is transferring all MPD1 and MPTT future development and marketing to our distribution partners in Asia and the United States. As such, the MPD1 activity which has been stalled since 4th Quarter 2013, will begin to have new life in 2014 and our partners will pick up the ball and aggressively pursue sales of MPD1 starting 3rd Quarter 2014. As a result of this, EPGL will be enabled to focus 100% on major development projects which are important to the Company while reinvigorating the MPD1 and MPTT projects under our partners efforts. Q1 2014 financials, to be released within 72 hours, will reflect the transition of MPD1 and MPTT transition activity to our marketing partners. EPGL is essentially returning to "start-up" mode under the major development projects underway. Our future has never been brighter than it is right now in our opinion and we are working everyday to bring very significant value to our shareholders. We are also working to enlighten the investment community at large, to the incredible activities we are up to lately, leading giants, as soon as we possibly can. EPGL MEMS is leading!
EPGL is leading the giants with cutting edge technology. "We're at a new beginning and ground floor for EPGL with our recent reconfiguration of focus on the most significant opportunities. We think our most loyal shareholders will be amazed and excited about what they are part of." -Michael Hayes, President, EPGL.
12. Daaaaamn! So, that answered that! Amazing stuff! But now I have another question. Why are they still technically called EPGL Global Communications and not EPGL Medical Sciences? I've heard here and there that they were supposed to change their name a while ago.
Because the former company, EPGL Global Communications, whom was a registered company with the SEC, de-registered back in 2009 as their troubles mounted. It is EPGL's plan to officially change their name when they re-register with the SEC. Which they had planned to do when they finished up the house keeping from the liquidation process. The former company made quite a mess of the ticker. Then things began to shift towards BioMEMs and the possibility of being bought out dramatically increased. EPGL put off re-registering, simply put, because they may never have to. Why go through all of that if you get bought out? Right now, EPGL is waiting to see what happens. Once the dust settles they have more clear picture of the future of the company, they will re-register and be formerly recognized as 'EPGL Medical Sciences' by the powers that be, if need be.
13. Well, my mind has just been blown! This is all just plain awesome! Thanks a ton. I will continue with my DD. I look forward to becoming a long term holder of this. Before you go, anything else I should look at?
Sure. Check out this timeline since EPGL was formed. It will show their accomplishments to date and hopefully answer any other questions you might have. Cheers and good luck.
June 27th, 2012
EP Global Communications, Inc. Achieves Shareholder Approval for Restructuring and Signs Definitive Restructuring Agreement
Company Becomes Medical Device Manufacturer and Marketer
This is a MUST read
July 11th, 2012
EP Global Communications, Inc., Announces the Appointment of Corey W. Hunter M.D. as Company Medical Director and Chairman of Scientific Advisory Board. Respected Pain Physician Headed a Team of Scientists at NYU for Early Findings on the FDA Cleared MPDD Device. Will Now Lead Device to the U.S. and International Healthcare Markets.
All the toxic debt has now been eliminated and there will be no unscrupulous dumping of shares into the market as service to debt ever again. The restructuring partners will never consider such a financing arrangement in the future and will not allow that predicament to occur to the Company or its shareholders again. In contrast, the restructuring partners of the Company are committed to growing the Company and shareholder value significantly for the long term.
Corey Hunter, M.D. & Elimination of Toxic Debt
July 26th, 2012
EP Global Communications, Inc. Announces Friday July 27, 2012 as Effective Date for Approved Reverse Split
EP Global Communications, Inc., announces that FINRA has set Friday July 27, 2012 as the market effective date for the 10:1 reverse split of common outstanding shares. The Company shareholders previously approved the reverse split on June 8, 2012.
As a result, the Company will eliminate 100% of major debt and effectuate a new direction into the medical device manufacturing and marketing sector.
August 21st, 2012
EPGL Launches Twitter account and begins to update shareholders regularly with tweets and Q&A sessions
Twitter Page
August 30th, 2012
EP Global Communications, Inc., Announces First Orders for MPDD Medical Device and the Addition of Eric Lee M.D. M.A. to Medical Team
September 5th, 2012
EPGL Med conducts it’s 1st Q&A session for investors via Twitter. They discuss the MPDD along with it’s potential, and company plans for the future, etc, etc.
Investor Q&A #1
September 24th, 2012
EP Global Communications, Inc. Lands One of the World's Leading Biomedical Engineers.
David T. Markus holds a Ph.D. in Biomedical Engineering and a MS in Electrical Engineering with an emphasis in MEMS Microelectronics and Biomedical. The worldwide market for Bio-MEMS medical technology is estimated to grow into hundreds of billions of dollars over the next several years in healthcare as well as other technological markets. The Company plans to aggressively pursue new technology opportunities in this field of medical technology.
EPGL hires David T. Markus Ph.D
September 26th, 2012
EPGL Launches Website
EPGL Website
September 26th, 2012
EPGL Med conducts it’s 2nd Q&A session via Twitter for investors. They discuss fundamentals, management, the MPDD, etc, etc.
Twitter page detailing Investor Q&A #2
October 9th, 2012
Ryan M. Stellar M.E. B.E. joins Corey Hunter M.D., Eric Lee, M.D.M.A. and David T. Markus Ph.D. on the EPGL Team.
EPGL Team
October 17th, 2012
EPGL Med conducts 3rd Q&A session via Twitter with investors. They discuss new staff, sales goals, etc, etc.
Twitter page detailing Investor Q&A #3
November 28th, 2012
EP Global Communications, Inc. Releases Dramatically Improved Balance Sheet After Restructuring, Announces New Assets
For the First Time in Two Years, Company Begins to Report Again and Move Up OTC Tiers on the Way to Full SEC Reporting in 2013
EPGL Begins Reporting. Sheds 'No Info Status'
November 28th, 2012
EPGL is announcing today for the first time, it has acquired significant new assets other than the MPDD device rights, in the BioMEMS arena. BioMEMS will be a major focus for the Company going forward as previously announced.
BioMEMS devices are as important to the future of medicine as microprocessors were to the computer revolution at the end of the last century. BioMEMS is a science that includes more than simply finding biomedical applications for microelectromechanical systems devices. It represents an expansion into a host of new polymer materials, microfluidic physics, surface chemistries and their modification, 'soft' fabrication techniques, biocompatibility, and cost-effective solutions to biomedical problems. It brings together the creative talents of electrical, mechanical, optical, and chemical engineers, materials specialists, clinical laboratory scientists, and physicians. BioMEMS devices are the platform upon which nanomedicine will be delivered.
EPGL Enters bioMEMS Arena
November 28th, 2012
EPGL Med conducts it’s 4th Q&A session via Twitter with investors. They talk about entering the bioMEMS industry, getting to current status, etc, etc.
Investor Q&A #4
December 31st, 2012
EPGL Med files EP Global Communication's Annual Reports containing Income Statements and Balance Statements from 2010 and 2011
Balance Statement 2010
Income Statement 2010
Balance Statement 2011
Income Statement 2011
December 31st, 2012
EPGL Med files it's Articles of Incorporation
Articles of Incorporation
December 31st, 2012
EPGL Med files it's Bylaws
Bylaws
January 4th, 2013
EPGL Med conducts it’s 5th Q& with investors via Twitter. They reaffirms their goal of meeting all of the requirements of uplisting to the OTCQX U.S, the company’s share structure, etc, etc
Investor Q&A #5
January 4th, 2013
Via Twitter, EPGL Med selects a Singapore based firm for its Asia distribution. This, among other news will be detailed in January 25, 2013 announcements.
@EPGLMed
January 8th, 2013
EPGL Med files it's 2012 Annual Report, Initial Company Information and Disclosure Statement
*Highlights
Quote:
Sharestructure
5,000,000,000 Authorized Common
4,668,000,000 Outstanding
499,161,167 Freely trading
The Company plans to manufacture, market and develop several new medical devices. Over the next 12 months, the company will seek strategic partners in equity finance, manufacturing and distribution to achieve these objectives.
The Company will not restructure again or propose any further reverse splits now or in the future. The Company believes it has more than adequate cash resources to see operations through the next 12 months.
Chronic back pain treatment in the United States alone is estimated to cost nearly $100 billion dollars annually. Utilizing recent Bureau of Labor Statistics data an estimate for the potential U.S. market for the MPDD is $2 billion and an additional $2.5 billion
globally, for a total potential market of $4.5 billion.
The Company projects that within 6 months of market launch, sales have the potential to exceed 2000 units per month worldwide and generating $10 million dollars per month.
2012 Annual Report
January 8th, 2013
EPGL Med files Supplemental Information to the OTC.
Statement of Cash Flow For the 12 Months Ended December 31, 2010.
2010 Cash Flow of Former Company
January 8th, 2013
EPGL Med files Supplemental Information to the OTC.
Statement of Cash Flow For the 12 Months Ended December 31, 2011.
2011 of Former Company
January 10th, 2013
EPGL files it's Attorney Letter to the OTC, meeting the requirements needed to be uplisted from 'Limited Information' to 'Current Status'.
Attorney Letter to OTC
January 10th, 2013
EPGL Med Files Supplemental Information - Financial Report Year to Date as of December 31,2012 - Amended
2012 Annual Report Ammendment
January 11th, 2013
EPGL is Uplisted to OTC Current Information!
January 11th, 2013
EPGL announces that all EPGL restricted shares were issued late in year 2012 with 99% of them being issued after December 20, 2012. The controlling shareholders, PWC/AJW Qualified/Hayes have all committed to long term growth of EPGL and will not enter any agreements where restricted shares can be "dumped" into the market. If any shareholder is not clear on this, they can contact EPGL investor relations for further clarification.
Contact Brady Peterson at EPGL Investor Relations
January 25th, 2013
EPGLMed Issues Press Release.
The PR highlights EPGL’s success at landing a worldwide distribution deal in Singapore and a manufacturing deal in San Diego. Furthermore, they named March 29th, 2013 as the date they will announce when the MPDD’s get officially released. Also highlighted are the 6 new devices that EPGL is currently developing within the BioMems field.
Lastly, they announced new team members, Noah T. Kaufman, M.D. as Vice President of Emergency Medicine Innovations, Mark Rea as Innovations Advisor and Reid H. Erickson as Financial Partnership Strategy Advisor.
Worldwide Distribution Channel & Manufacturing Deal Announced along with New BioMems Devices, etc, etc
January 25th, 2013
EPGL conducts it’s first ever conference call for shareholders.
Michael Hayes talks about share structure and EPGL’s & PwC’s commitment to creating shareholder value, company goals of becoming a 50 Billion dollar company listed on the Nasdaq or NYSE, etc, etc. Listen to it. Starts 0:35.
Highlights include the Restricted Share Structure and how and why those shares will never enter the float.
Introductions of Staff.
Long term goals of the company.
etc, etc, etc. Just listen to the thing!
EPGL Conference Call
January 30th, 2013
In accordance with the 2012 Restructuring Agreement, EPGL has acquired the option and right of first refusal to all AJW / Pricewaterhouse Coopers controlled holdings. This includes up to 2.25 billion of RESRICTED common shares.
EPGL Granted 1st refusal of AJW's 2.25 Billion shares!
February 22, 2013
EPGL Receives First Physician Review of MPDD Device
Quote:
“As you know I have had the opportunity to purchase and implement the Muscle Pain Detection Device into my pain management practice. I just wanted to give you some feedback as to my experience with the device, which up to this point has been quite encouraging..........cont”
Physician Review of the MPDD
February 25th, 2013
EP Global Communications, Inc. Announces Major Shareholder Update and Events Coming for March 2013. New Patents Being Filed and First Medical Device Release Among Topics
First, the Company announces that up to 12 new medical device patents will be filed in the month of March, 2013......
Second, the MPDD device will be released on March 25, 2013......
Third, the MPTT (Muscle Pain Trigger-Point Treatment) is being put on a track to be released by December, 2013 pending FDA 510k approval..........
Fourth, DTC restrictions on some brokers are expected to be lifted at any moment. The Company counsel has filed all requisite documents and all brokers should have access to EPGL stock electronic deposit services, shortly......
Fifth, as shareholders know, the Company has achieved Current Information status with OTC Markets. Now, the Company plans to graduate the EPGL symbol to OTCQX by end of year 2013. Following that movement, the next goal will be to bring the Company to NASDAQ or NYSE sometime in 2014.....
Shareholder Update
February 25, 2013
EPGL Conducts it’s 6th Investor Q&A via Twitter. They discuss the timetable in up listing to the OTCQX, the DTC restrictions being lifted, product development, and much, much more.
Investor Q&A #6
March 21st, 2013
EP Global Communications, Inc, EPGL Medical Begins Selling MPDD Devices, Singapore Distributor Secures First 1,000 Units Off Assembly Line
EPGL Seeing High Demand Beginning for First New Medical Device Released in US and International Markets.
MPDD Hits the Market!
EP Global Communications, Inc. (the Company), is pleased to announce that the Company has begun selling MPDD units both in the US Market and Internationally. The exclusive Singapore distributor has secured the first 1,000 units to come off the assembly line. In addition, the Company is simultaneously engaging the top 20 international markets throughout the world in addition to the United States.
April 2nd, 2013
EPGL conducts it’s second Conference call for shareholders.
Conference Call
April 11th, 2013
Google Glass to be Integrated by Medical Device Maker EPGL Med and EP Global Communications, Inc.
Company to be Among the First to Develop Medical Device Applications for Newest Smart Technology
EPGL to Implement Google Glass Tech
EPGL will be among the first Medical Device Makers to Implement Google Glass technology and the API Mirror platform for use with its medical devices. EPGL Medical, a new medical device maker specializing in advanced technology for innovative hand-held medical devices, has several new devices in development under direction of David T. Markus Ph.D., which are being developed with the latest smart platforms in mind.
Also, In addition to integrating smart technology such as Google Glass, EPGL Medical now has a "secret weapon" medical device technology advancement which no other medical device company has. This single technology will be the catalyst for dozens of new medical device technologies to be produced or licensed by the Company. The Company is in the process of filing more than 50 patents to protect this unique and valuable innovation.
April 11th, 2013
EPGL announces that is in talks to have a leading East Coast PR firm to dramatically increase exposure to the broader investment community. This will be put in place by end of April 2013 for the purpose of educating investors worldwide of the undervalued nature of EPGL presently.
EPGL Twitter
April 18th, 2013
EPGL announces that it has established Distribution in the 20 Global Markets and is working on establishing distribution with the Middle East to New Zealand.
EPGL Twitter
April 22nd, 2013
New BioMEMS Medical Device Platform "TopSpin" to Be Revealed by EPGL Medical and EP Global Communications, Inc., During "7 Days in April" Conference Call Series
David T. Markus Ph.D. Will Host Live Conference Call Series Starting April 24 through April 30, 2013.
7 Days of April Event!
As one of the top BioMEMS engineers in the world, Dr. Markus along with others, will unveil the importance and value of EPGL's new BioMEMS device platform in today's medical marketplace. The new technology stands to spawn potentially dozens of new medical devices, giving doctors innovative new tools for diagnosis and treatment.
May 16th, 2013
EPGL Files 1st Quarter Report along with
Q1 Balance Sheet, Income Statement & Cash Flow Statement
Q1 Balance Sheet, Income Statement & Cash Flow Statement
Cash & cash Equivilants: $12,868,500
Intellectual Property: $1,088,602,000
Total assets: $1,257,653,000 Q1 Report
Share Structure as of March 31st, 2013
5 Billion Authorized Common
4,668,229,167 Outstanding
4,169,068,000 Restricted
499,161,167 Tradable Float
May 20th, 2013
Article Published By Major Medical Device Magazine, MD-DI
Will EPGL's TopSpin Serve Up the Next Generation of Medical Devices?
A former DARPA scientist and a device startup want to change medical devices forever using bioMEMS
MD-DI Article
June 14th, 2013
Review Published by Manhattan Sports & Spine Medicine regarding MPDD
New Technology Promises Hope for Chronic Muscle Pain.
Manhattan Sports & Spine Medicine review of MPDD
June 18th, 2013
EPGL Medical Unveils New Devices and Intellectual Property Under EP Global Communications, Inc. Ownership
Advanced Device Prototypes on the Way Along with FDA 510k and PMA Applications.
New Devices and Intellectual Property
1. A new advanced ablation device for nerve pain treatment in the back.
2. A new advanced ablation device for nerve treatment of Facial Glabballar Frowning.
3. A new advanced device for elimination of facial wrinkles.
4. A new advanced Epidural device.
5. A new advanced power source for TopSpin medical devices.
6. A new and promising device for treatment of Retinitis Pigmentosa
7. A new and promising device for treatment of Macular Degeneration
8. A new and promising treatment for Hearing Loss
9. A new more accurate treatment for trigger points in the muscles (MPTT)
10. A new advanced device for treatment of prostate tumors.
11. A new advanced endoscopic device.
12. A new advanced device for delivery of micron sized drug payloads.
13. A new advanced device for delivery of micro mechanical devices into the body.
14. A new advanced device for biopsy.
15. A new advanced device for stem cell treatment delivery.
16. A new advanced contact lens device.
June 25th, 2013
DTCC Chill Lift is Authorized
Company Will Immediately Move to File with SEC for Up-Listing EPGL Ticker
DTCC Chill Lift is Authorized
“EPGL is pleased to announce that DTCC counsel has confirmed their authorization for removal of the DTCC Chill on EPGL ticker. The Company is also announcing that it will immediately move to file SEC forms for up-listing the Company to a higher stock exchange.”
July 29th, 2013
EPGL Medical Invents Self Powered Contact Lenses for Medical and Consumer Applications.
"Using cutting edge technology, EPGL has invented a self perpetuating power source for lenses which does not require external energy such as RF," said David Markus PhD. "The market for contact lenses as information data display devices is just beginning and will be a natural extension of new wearable data devices such as Google Glass." EPGL intends to license the new technology to companies who are developing data display for contact lenses.
Invention Powers Contact Lenses Day or Night from Within
August 7, 2013
EPGL Medical Invents New Cell Regeneration Technology For Eye Disease
EPGL engineers have invented a new device for the purpose of treating serious eye diseases such as macular degeneration and retinitis pigmentosa. The technology emits low intensity pulse ultrasound into the eye for the purpose of regeneration of damaged cells and to possibly arrest the degeneration of existing healthy cells within the macula and the entire retina.
"The technology has proven to be very effective in recent research. We now have the ability to use MEMS to put the technology into the micro size environment for contact lenses.
EPGL Medical Invents New Cell Regeneration Technology For Eye Disease
August 12, 2013
EPGL Medical Invents Smart Epidural Needle, Nerve Ablation And Trigger Point Treatment Devices
New Smart Medical Devices Will Give Physicians Advanced Situational Awareness During Critical Procedures.
"EPGL is a company that is amassing advanced device technologies at a rapid pace and will make its mark with development of smarter medical devices." said David T. Markus PhD. "We have the advantage in advanced MEMS technology and this is the field that will revolutionize medicine in the next several years. EPGL shareholders are in a very special company at a special time."
EPGL Medical Invents Smart Epidural Needle, Nerve Ablation And Trigger Point Treatment Devices
August 15, 2013
EPGL files 2nd Quarter 2013 Report . April 1st thru June 30th.
2nd Quarter Report
August 15, 2013
EPGL Files 2nd Quarter 2013 Financial Statements
Cash Balance at Beg of Period
$12,868,000.50
Cash and Cash Equivalents June 30, 2013
$15,690,000.50
Increase of $2,822,000
EPGL 2nd Quarter 2013 Finacials
September 15th, 2013
AJW Investor Update
AJW Investor Update
November 15th, 2013
Epgl Files 3rd Quarter 2013 Financial Statements.
Cash and cash equivalents: $19,332,500
Total Assets: $1,785,321,500
Supplemental Information
3rd Quarter 2013 Financials
December 16th, 2013
EPGL Technology Selected by Major Corporation for Development
In a first for the company, one of EPGL's advanced technologies has been selected by a multi-billion dollar, NYSE publicly traded industry leader for development and integration into new products. "This is the biggest development for our company in its history," said David T. Markus PhD.”
EPGL Technology Selected by Major Corporation for Development
January 14th, 2014
Pricewaterhouse Coopers, Ian Stokoe, pens letter confirming the deal EPGL made with a muti-billion dollar NYSE company.
......"In my view, this is a significant milestone and, as a major shareholder, I look forward to the future success of EPGL."
PWC Letter
February 11, 2014
EPGL Developing Wearable Tech
EP Global Communications, Inc., (OTC Ticker EPGL) announces that as of fourth quarter 2013, EPGL has focused 100% on development of smart wearable technology. Because of recent developments and opportunities before the Company, EPGL has now established itself as an early player in the growing field. "Leading industry insiders believe wearable smart technology will be as large as the smart phone revolution. We agree with that," says David Markus Ph.D. while referencing Wired Magazine's January 2014 Cover Story. "Our unique technology and know-how, puts EPGL in demand. We've talked about this in our announcements since mid-2013."
"EPGL is very fortunate to be among a few serious players right now, who are pioneering this technology. These are visionary companies and people at the top of their field. We're swimming with the big fish and nobody knows who we are just yet," said Michael Hayes, Company President. "But they will in due time."
EPGL Developing Wearable Tech
February 20th, 2014
Q4 2013 Quarterly Report
February 23rd, 2014
Supplemental Information Ammended Q4 Financials
March 18th, 2014
EPGL Shareholder Update: Meetings in Bay Area Recently, Went Well. EPGL is Positioned with Industry Leaders on Innovation of Wearables.
April 15th, 2014
EPGL Shareholder update: EPGL Announced Advanced Contact Lens Technology in August of 2013. Since then our technology and know how has caught the eyes of the world's leading companies in the field. Now, EPGL is on the forefront of innovating the technology and EPGL MEMS will be inside the world's most advanced contact lenses as we move into this new revolution of smart, wearable technology.
EPGL technologies are on the cutting edge and in demand. We believe current dedicated shareholders will be proven to be "visionary".
May 15th, 2014
EPGL Shareholder Update: As EPGL has now transitioned to focus on a major MEMS technology development, the Company is transferring all MPD1 and MPTT future development and marketing to our distribution partners in Asia and the United States. As such, the MPD1 activity which has been stalled since 4th Quarter 2013, will begin to have new life in 2014 and our partners will pick up the ball and aggressively pursue sales of MPD1 starting 3rd Quarter 2014. As a result of this, EPGL will be enabled to focus 100% on major development projects which are important to the Company while reinvigorating the MPD1 and MPTT projects under our partners efforts. Q1 2014 financials, to be released within 72 hours, will reflect the transition of MPD1 and MPTT transition activity to our marketing partners. EPGL is essentially returning to "start-up" mode under the major development projects underway. Our future has never been brighter than it is right now in our opinion and we are working everyday to bring very significant value to our shareholders. We are also working to enlighten the investment community at large, to the incredible activities we are up to lately, leading giants, as soon as we possibly can. EPGL MEMS is leading!
EPGL is leading the giants with cutting edge technology. "We're at a new beginning and ground floor for EPGL with our recent reconfiguration of focus on the most significant opportunities. We think our most loyal shareholders will be amazed and excited about what they are part of." -Michael Hayes, President, EPGL.
May 18th, 2014
Q1 2014Balance Sheet, Income Statement & Cash Flow Statement
May 30th, 2014
EPGL Shareholder Update: EPGL achieves Phase 2 of advanced technology development project. Another milestone and now closer to revelation for long shareholders.
June 19th, 2014
EPGL Shareholder Update: EPGL is leading the advance MEMS technology design and product development for one of the largest companies in its field. The relationship has expanded under phase two and involves co -ownership of product technologies under development. All EPGL technologies are involved. The technology and products will be manufactured by the NYSE company branded under its name and distributed worldwide, by that Company and others affiliated. EPGL's role is that of research, design, development and ownership of the various technology applications. We are developing an "open source" platform with this company to enable many other organizations and entities to create new products with a new platform. EPGL shareholders should realize that this situation is very real and developing. We are getting very much closer to the time we can reveal all. This will happen no later than August 29, 2014.
EPGL is unlike any other OTC Pink Sheet company at this time. Shareholders are right to be excited about our future. By the way,EPGL and our partners could make an announcement sooner that August 29, 2014.
June 30th, 2014
Q1 2014 Disclosure Statement Update
July 17th, 2014
EPGL Shareholder Update: Google took glucose lens as far as they could. Now the "X" man is an ex-man. Enter Novartis to try to figure it out. But Novartis reached out to EPGL not long ago. So whose technology will dominate coming smart lens revolution? EPGL is leading giants and focused on new smart lens technologies which will enable mass marketing in both health and consumer electronics well into the future. Many companies and institutions stand to be enabled by our work. EPGL is working with the best in the business and more is to come by August 29, 2014. EPGL shareholders should be excited at the prospects.
July 18th, 2014
EPGL Shareholder Update: It can now be revealed that both Novartis and Google reached out to our development team members in recent weeks and months. This fact should be a clue to the gravity and know-how of our team in both BioMEMS and manufacturing of smart contact lenses. We intend to set the industry's standard with our enabling technology. Who are we teamed up with? Who will ultimately include EPGL originated technology.
(0)
(0)Scroll down for more posts ▼